lestaurtinib has been researched along with tretinoin in 3 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (tretinoin) | Trials (tretinoin) | Recent Studies (post-2010) (tretinoin) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 23,654 | 1,083 | 6,085 |
| Protein | Taxonomy | lestaurtinib (IC50) | tretinoin (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 0.18 | |
| Adenosine receptor A3 | Homo sapiens (human) | 5.275 | |
| Retinoic acid receptor alpha | Homo sapiens (human) | 2.2542 | |
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 5.3 | |
| Retinoic acid receptor beta | Homo sapiens (human) | 0.7537 | |
| Retinoic acid receptor alpha | Mus musculus (house mouse) | 0.0057 | |
| Retinoic acid receptor gamma | Homo sapiens (human) | 0.0064 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 5.275 | |
| Retinoic acid receptor gamma | Mus musculus (house mouse) | 0.004 | |
| Retinoic acid receptor beta | Mus musculus (house mouse) | 0.005 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.576 | |
| Nuclear receptor ROR-alpha | Homo sapiens (human) | 0.1995 | |
| Alpha-synuclein | Homo sapiens (human) | 3 | |
| Cellular retinoic acid-binding protein 1 | Gallus gallus (chicken) | 0.5233 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.358 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 5.275 | |
| Retinoic acid receptor RXR-gamma | Homo sapiens (human) | 0.35 | |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | 0.1995 | |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 5.3 | |
| Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | 0.82 | |
| 60 kDa chaperonin | Escherichia coli | 6.7 | |
| 10 kDa chaperonin | Escherichia coli | 6.7 | |
| Nuclear receptor ROR-beta | Homo sapiens (human) | 0.1259 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burnett, AK; Gale, RE; Gilkes, AF; Grimwade, D; Hills, R; Kottaridis, PD; Linch, DC; Mills, KI; Nugent, E; Pizzey, AR; Solomon, E; Swirsky, D; Wheatley, K | 1 |
| Tallman, M | 1 |
| Karp, J | 1 |
3 other study(ies) available for lestaurtinib and tretinoin
| Article | Year |
|---|---|
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Carbazoles; Child; Child, Preschool; Female; fms-Like Tyrosine Kinase 3; Furans; Gene Expression Profiling; Humans; Indoles; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Prognosis; Survival Analysis; Tretinoin | 2005 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |